Header Logo

Connection

Reina Haque to Aged

This is a "connection" page, showing publications Reina Haque has written about Aged.
Connection Strength

1.463
  1. Patterns of overall mortality by race/ethnicity and socioeconomic status in insured cancer patients in Southern California. Cancer Causes Control. 2021 Jun; 32(6):609-616.
    View in: PubMed
    Score: 0.088
  2. SARS-CoV-2 Testing, Positivity Rates, and Healthcare Outcomes in a Cohort of 22,481 Breast Cancer Survivors. JCO Clin Cancer Inform. 2021 02; 5:168-175.
    View in: PubMed
    Score: 0.087
  3. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017 Oct 10; 117(8):1233-1240.
    View in: PubMed
    Score: 0.068
  4. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017 May - Jun; 57(3):303-310.e2.
    View in: PubMed
    Score: 0.066
  5. Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
    View in: PubMed
    Score: 0.065
  6. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
    View in: PubMed
    Score: 0.062
  7. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.060
  8. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55.
    View in: PubMed
    Score: 0.058
  9. Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86-92.
    View in: PubMed
    Score: 0.053
  10. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract. 2014 Jul-Aug; 8(4):e374-81.
    View in: PubMed
    Score: 0.052
  11. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev. 2013 Feb; 22(2):313-6.
    View in: PubMed
    Score: 0.049
  12. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318-27.
    View in: PubMed
    Score: 0.049
  13. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55.
    View in: PubMed
    Score: 0.048
  14. Preventive care and health behaviors among overweight/obese men in HMOs. Am J Manag Care. 2012 Jan; 18(1):25-32.
    View in: PubMed
    Score: 0.046
  15. Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2120-6.
    View in: PubMed
    Score: 0.045
  16. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
    View in: PubMed
    Score: 0.041
  17. Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan. Cancer. 2007 Jul 15; 110(2):275-81.
    View in: PubMed
    Score: 0.034
  18. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 2005 Apr 18; 221(1):61-5.
    View in: PubMed
    Score: 0.029
  19. An automated data algorithm to distinguish screening and diagnostic colorectal cancer endoscopy exams. J Natl Cancer Inst Monogr. 2005; (35):116-8.
    View in: PubMed
    Score: 0.028
  20. The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Gu?rin in Treating Nonmuscle-Invasive Bladder Cancer. J Urol. 2024 Sep; 212(3):420-430.
    View in: PubMed
    Score: 0.027
  21. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Gynecol Oncol. 2020 12; 159(3):804-810.
    View in: PubMed
    Score: 0.021
  22. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
    View in: PubMed
    Score: 0.016
  23. Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. Breast Cancer Res Treat. 2017 01; 161(2):375-384.
    View in: PubMed
    Score: 0.016
  24. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
    View in: PubMed
    Score: 0.016
  25. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.015
  26. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
    View in: PubMed
    Score: 0.015
  27. Statins and hip fracture risk in men: a population-based case-control study. Ann Epidemiol. 2015 Nov; 25(11):844-8.
    View in: PubMed
    Score: 0.015
  28. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.015
  29. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
    View in: PubMed
    Score: 0.014
  30. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014 Jul; 146(2):401-9.
    View in: PubMed
    Score: 0.014
  31. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
    View in: PubMed
    Score: 0.013
  32. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. Prostate. 2013 Sep; 73(13):1371-7.
    View in: PubMed
    Score: 0.013
  33. Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013 Jun; 61(6):888-95.
    View in: PubMed
    Score: 0.013
  34. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.013
  35. Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study. BMC Urol. 2013 Feb 20; 13:12.
    View in: PubMed
    Score: 0.012
  36. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.012
  37. A comparison of lifestyle and behavioral cardiovascular disease risk factors between Asian Indian and White non-Hispanic men. Ethn Dis. 2012; 22(2):168-74.
    View in: PubMed
    Score: 0.012
  38. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol. 2012 Jan; 187(1):185-9.
    View in: PubMed
    Score: 0.011
  39. Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. J Urol. 2011 Apr; 185(4):1388-93.
    View in: PubMed
    Score: 0.011
  40. Red wine consumption and risk of prostate cancer: the California men's health study. Int J Cancer. 2010 Jan 01; 126(1):171-9.
    View in: PubMed
    Score: 0.010
  41. Red wine consumption not associated with reduced risk of colorectal cancer. Nutr Cancer. 2010; 62(6):849-55.
    View in: PubMed
    Score: 0.010
  42. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.010
  43. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.010
  44. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
    View in: PubMed
    Score: 0.010
  45. Generational status and duration of residence predict diabetes prevalence among Latinos: the California Men's Health Study. BMC Public Health. 2009 Oct 19; 9:392.
    View in: PubMed
    Score: 0.010
  46. Racial disparities in erectile dysfunction among participants in the California Men's Health Study. J Sex Med. 2009 Dec; 6(12):3433-9.
    View in: PubMed
    Score: 0.010
  47. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
    View in: PubMed
    Score: 0.010
  48. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010 Jan; 63(1):64-74.
    View in: PubMed
    Score: 0.010
  49. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
    View in: PubMed
    Score: 0.010
  50. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008 Oct 08; 300(14):1660-4.
    View in: PubMed
    Score: 0.009
  51. Abstracting height and weight from medical records, and breast cancer pathologic factors. Cancer Causes Control. 2008 Dec; 19(10):1217-26.
    View in: PubMed
    Score: 0.009
  52. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
    View in: PubMed
    Score: 0.009
  53. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol. 2007 Nov; 20(11):1149-55.
    View in: PubMed
    Score: 0.009
  54. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008 Feb; 107(3):397-403.
    View in: PubMed
    Score: 0.008

© 2024 Kaiser Permanente